Targeted Therapy in Thyroid Cancer: State of the Art

Elisei, 2010, Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question, J Clin Endocrinol Metab, 95, 1516, 10.1210/jc.2009-1536

Luster, 2012, Radioiodine therapy of metastatic lesions of differentiated thyroid cancer, J Endocrinol Invest, 35, 21

Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838

Chiacchio, 2008, Anaplastic thyroid cancer: prevalence, diagnosis and treatment, Minerva Endocrinol, 33, 341

Pacini, 1991, Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens, Am J Clin Pathol, 95, 300, 10.1093/ajcp/95.3.300

Orlandi, 1994, Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer, Ann Oncol, 5, 763, 10.1093/oxfordjournals.annonc.a058984

De Besi, 1991, Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer, J Endocrinol Invest, 14, 475, 10.1007/BF03346846

Viola, 2016, Treatment of advanced thyroid cancer with targeted therapies: ten years of experience, Endocr Relat Cancer, 23, R185, 10.1530/ERC-15-0555

Cancer Genome Atlas Research Network, 2014, Integrated genomic characterization of papillary thyroid carcinoma, Cell, 159, 676, 10.1016/j.cell.2014.09.050

Romei, 2016, A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma, Nat Rev Endocrinol, 12, 192, 10.1038/nrendo.2016.11

Yoo, 2016, Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers, PLoS Genet, 12, e1006239, 10.1371/journal.pgen.1006239

Landa, 2016, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers, J Clin Invest, 126, 1052, 10.1172/JCI85271

Romei, 2016, New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations, J Med Genet, 10.1136/jmedgenet-2016-103833

Ciampi, 2013, Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series, Thyroid, 23, 50, 10.1089/thy.2012.0207

Yaish, 1998, Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors, Science, 242, 933, 10.1126/science.3263702

Lin, 2012, Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy, PLoS One, 7, e46726, 10.1371/journal.pone.0046726

Xing, 2013, Molecular pathogenesis and mechanisms of thyroid cancer, Nat Rev Cancer, 13, 184, 10.1038/nrc3431

Burrows, 2010, Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas, Endocr Relat Cancer, 17, 61, 10.1677/ERC-08-0251

Zerilli, 2010, BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer, Mod Pathol, 23, 1052, 10.1038/modpathol.2010.86

Ramirez, 2000, Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma, Clin Endocrinol, 53, 635, 10.1046/j.1365-2265.2000.01124.x

Rong, 1994, Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation, Proc Natl Acad Sci USA, 91, 4731, 10.1073/pnas.91.11.4731

Scarpino, 2004, Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid, J Pathol, 202, 352, 10.1002/path.1522

Wells, 2012, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial, J Clin Oncol, 30, 134, 10.1200/JCO.2011.35.5040

Elisei, 2013, Cabozantinib in progressive medullary thyroid cancer, J Clin Oncol, 31, 3639, 10.1200/JCO.2012.48.4659

Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9

Schlumberger, 2015, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N Engl J Med, 372, 621, 10.1056/NEJMoa1406470

Grande, 2013, Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies, Adv Ther, 30, 945, 10.1007/s12325-013-0069-5

Fox, 2013, Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma, Clin Cancer Res, 19, 4239, 10.1158/1078-0432.CCR-13-0071

Leboulleux, 2012, Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial, Lancet Oncol, 13, 897, 10.1016/S1470-2045(12)70335-2

Bastholt, 2016, Effect of an outreach programme on vandetanib safety in medullary thyroid cancer, Eur Thyroid J, 5, 187, 10.1159/000448919

Schlumberger, 2015, Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.6012

Schlumberger M, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving open-label sorafenib post-progression on the phase III DECISION trial. Presented at: European Thyroid Congress 2014; September 2014; Santiago de Compostela, Spain. Abstract OP87.

Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655

Habra MA, Song JH, Rietschel P. Outcomes by site of metastasis for patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib versus placebo: results from a phase 3, randomized trial. Presented at: 15th International Thyroid Congress 2015; 18–23 October 2015, Orlando, Florida, USA, Abstract 55.

Brose MS, Teng A, Rietschel P, Habra MA. Lenvatinib and the effect of age on overall survival for patients with radioiodine-refractory differentiated thyroid cancer. Presented at: 15th International Thyroid Congress 2015; 18–23 October 2015, Orlando, Florida, USA, Abstract 731.

Elisei, 2015, Subgroup analysis according to differentiated thyroid cancer histology in phase 3 (SELECT) trial of lenvatinib, Oncol Res Treat, 38, 1

Schlumberger, 2016, A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer, Clin Cancer Res, 22, 44, 10.1158/1078-0432.CCR-15-1127

Schlumberger, 2014, Definition and management of radioactive iodine-refractory differentiated thyroid cancer, Lancet Diabetes Endocrinol, 2, 356, 10.1016/S2213-8587(13)70215-8

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Giraudet, 2008, Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times, Eur J Endocrinol, 158, 239, 10.1530/EJE-07-0667

Miyauchi, 2011, Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy, Thyroid, 21, 707, 10.1089/thy.2010.0355

Cabanillas, 2012, Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma, Endocr Relat Cancer, 19, C19, 10.1530/ERC-11-0371

Deandreis, 2011, Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?, Endocr Relat Cancer, 18, 159, 10.1677/ERC-10-0233

Schlumberger, 2012, European thyroid association guidelines for metastatic medullary thyroid cancer, Eur Thyroid J, 1, 5, 10.1159/000336977

Bonichon, 2015, Local treatment of metastases from differentiated thyroid cancer, Ann Endocrinol (Paris), 76, S40, 10.1016/S0003-4266(16)30013-0

Panteli, 2016, Pharmaceutical regulation in 15 European countries review, Health Syst Transit, 18, 1

Viola, 2013, Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer, Future Oncol, 9, 1083, 10.2217/fon.13.128

Salmon, 2017, A new paradigm for clinical communication: critical review of literature in cancer care, Med Educ, 51, 258, 10.1111/medu.13204

Workman, 1992, Tyrosine kinase inhibitors, Semin Cancer Biol, 3, 369